The contribution of germline pathogenic variants in breast cancer genes to contralateral breast cancer risk in brca1/brca2/palb2-negative women

HIGHLIGHTS

SUMMARY

Advances in the treatment of breast cancer (BC) over recent decades have substantially improved the survival rates of women with BC, thereby increasing the population of women at risk of a second primary BC. Treatment for the first BC is also known to modify subsequent CBC risk and has been studied in combination with specific genetic risk factors; examples include the use of tamoxifen in carriers of pathogenic germline variants (PGVs) in BRCA1 and BRCA2 and the effects of radiation exposure in combination with pathogenic variants in ATM. Carriers of PGVs in BRCA1 and . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.